Opus Genetics, Inc. Interest Expense Nonoperating
Opus Genetics, Inc. (IRD) reported Interest Expense Nonoperating of $143.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Opus Genetics, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $74.00K.
- Opus Genetics, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $69.00K.
- Opus Genetics, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $61.00K.
- Opus Genetics, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $68.00K.
- Opus Genetics, Inc. interest expense nonoperating for fiscal 2025 was $129.00K.
- Opus Genetics, Inc. interest expense nonoperating for fiscal 2024 was $0.00.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $143.00K 10-Q · filed 2026-08-06 | $204.00K derived: sum of 3 quarters · filed 2026-08-06 | $272.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $69.00K 10-Q · filed 2026-05-12 | $130.00K derived: sum of 2 quarters · filed 2026-05-12 | $198.00K derived: sum of 3 quarters · filed 2026-05-12 | $198.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $61.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $129.00K derived: sum of 2 quarters · filed 2026-03-12 | $129.00K derived: sum of 3 quarters · filed 2026-08-06 | $129.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $68.00K 10-Q · filed 2025-11-12 | $68.00K derived: sum of 2 quarters · filed 2026-08-06 | $68.00K 10-Q · filed 2025-11-12 | $68.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |